Latest News of GSK
Jim Cramer Says GSK plc (GSK) 'Goes Higher'
By Yahoo! Finance |
2 days ago
The article discusses Jim Cramer's insights on stocks such as GSK plc and market dynamics during earnings season. It also covers GSK's settlement over Zantac and its ranking in Cramer's list. The impo...
GSK shares jump after landmark £1.68bn heartburn drug settlement
By Yahoo! Finance |
3 days ago
GSK's shares rose following a $2.2 billion settlement for Zantac lawsuits in the US. The settlement with 80,000 claimants alleging cancer risks was seen as a win for GSK, which will not impact its gro...
GSK Shares Climb on $2.2 Bln Zantac Lawsuit Settlement
By MarketWatch |
3 days ago
British pharmaceutical company GSK's shares rose as it settled the majority of U.S. lawsuits over its heartburn drug Zantac. GSK agreed to pay $2.2 billion to resolve 93% of cases, boosting shares by ...
-
GSK shares jump after settlement of 80,000 Zantac lawsuits in U.S
By Yahoo! Finance | 3 days agoGSK's stock rose 6% as they agreed to a $2.2 billion settlement for Zantac cancer lawsuits in the U.S., lower than expected. The settlement resolves 93% of cases, easing concerns for investors....
-
FTSE 100 Live 10 October: Index seen higher, GSK in $2.2bn Zantac settlement
By Yahoo! Finance | 3 days agoUS economic optimism drove the S&P 500 to its 44th record high this year, with a 0.7% gain. The strong performance suggests the economy's resilience, reducing expectations for rapid interest rate cuts...
-
UK firm GSK to pay $2.2bn over Zantac cancer claims
By Yahoo! Finance | 3 days agoGSK agrees to pay $2.2bn to settle US Zantac cancer cases. The settlements cover 93% of claims, including a whistleblower complaint. GSK denies wrongdoing, removing financial risks from ongoing litiga...
-
GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment Zantac
By The Guardian | 4 days agoBritish drugmaker GSK has agreed to pay up to $2.2 billion to settle 80,000 US cases linking cancer to Zantac. GSK denies liability but aims to resolve the litigation, benefiting shareholders and remo...
-
GSK to pay £1.7bn to settle claims Zantac caused cancer
By Yahoo! Finance | 4 days agoChina stocks plummeted after disappointing economic stimulus announcements. The Shanghai Composite fell 5.1%, with the CSI300 down 5.6%. Hong Kong's Hang Seng Index dropped 2.4%. Japan's Nikkei rose 0...
-
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
By Yahoo! Finance | 4 days agoGSK plc settles with plaintiff firms representing 80,000 Zantac product liability cases in the U.S., paying up to $2.2 billion. Despite settlements, GSK denies liability and aims to resolve legal unce...
-
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
By Yahoo! Finance | 1 week agoBird flu has been detected in 254 dairy herds across 14 states in the US. 16 human cases of H5 have been reported in 2024, leading to a collaboration between GSK, Sanofi, and CSL to produce vaccine co...
-
Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
By Yahoo! Finance | 1 week agoGSK, Sanofi, and CSL received $72 million from the US government to boost bird flu vaccine production due to a nationwide outbreak. The aim is to increase the supply to 10 million doses by Q1 2025....
-
GSK settles two California lawsuits related to heartburn drug Zantac
By Yahoo! Finance | 3 weeks agoBritish drugmaker GSK settles two lawsuits in California over cancer claims linked to Zantac, without admitting liability. Facing thousands of claims nationwide, GSK appeals a Delaware judge's decisio...
-
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic Alliances, and New Vaccine Launches
By Yahoo! Finance | 3 weeks agoGSK is experiencing growth amidst challenges, with a 13% sales increase and R&D innovations. However, facing declining U.S. vaccine sales and legal issues, GSK must manage risks carefully. Strategic o...
-
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
By MarketWatch | 3 weeks agoGSK's successful late-stage trial combined a respiratory syncytial virus vaccine with a shingles vaccine for adults 50+. The study showed a positive immune response and tolerable side effects, leading...
-
Stocks Generating Improved Relative Strength: GSK ADR
By Investor's Business Daily | 1 month agoGSK ADR's RS Rating increased from 63 to 72, indicating a positive trend. Stocks with RS Ratings over 80 in the early stages often perform well. GSK ADR is forming a cup without handle pattern with a ...